As leaders in topical treatments, Dechra is acutely aware of the complexities that surround the use of antibiotics and the importance of using them responsibly. To strengthen our position further, Dechra will be progressively introducing a range of SmartTab antibiotics and innovative practice support initiatives.
To help prevent the emergence of multiple drug resistant bacteria the clinician should always consider the following points:
SmartTabs easy double divisibility ensures accurate and flexible dosing to help avoid development of antibiotic resistance associated with under dosing.
SmartTabs natural meat flavouring encourages acceptance to help ensure the full course is completed.
SmartTabs come in a range of dose strengths for both dogs and cats, enabling you to treat all sizes of patient.
The introduction of Metrobactin (metronidazole) and Amoxibactin (amoxicillin) represent the next step in our commitment to improve options for treatment and promote the responsible use of antibiotics.
Metrobactin® is the first veterinary licensed metronidazole tablet for the treatment of anaerobic infection in dogs and cats. Amoxibactin® is the only flavoured double-divisible amoxicillin tablet for the treatment of skin, urinary, reproductive and airway infections in dogs and cats.
Cefabactin® is the third product to be launched in the SmartTab range of Antibiotics and is for the treatment of infections in dogs caused by bacteria susceptible to cefalexin such as respiratory tract infections, especially bronchopneumonia.
All products support our existing Clavudale® antibiotic that combines amoxicillin and clavulanic acid.